SEARCH

SEARCH BY CITATION

References

  • 1
    Alter JH. New kit on the block: evaluation of second–generation assays for detection of antibody to the hepatitis C virus. Hepatology 1992; 15: 350353.
  • 2
    Younossi Z, McHutchison J. Serological tests for HCV infection. Viral Hepatitis Rev 1996; 2: 161173.
  • 3
    Lee SR, Wood CL, Lane MJ, Francis B, Gust C, Higgs CM, Nelles MJ, et al. Increased detection of hepatitis C virus infection in commercial plasma donors by a third-generation screening assay. Transfusion 1995; 35: 845849.
  • 4
    Uyttendaele S, Claeys H, Mertens W, Verhaert H, Vermylen C. Evaluation of third–generation screening and confirmatory assays for HCV antibodies. Vox Sang 1994; 66: 122129.
  • 5
    Barrera JM, Francis B, Ercilla G, Nelles M, Achord D, Darner J, Lee SR. Improved detection of anti-HCV in post-transfusion hepatitis by a third-generation ELISA. Vox Sang 1995; 68: 1518.
  • 6
    Garcia-Samaniego J, Enriquez A, Soriano V, Gutierrez M, Baquero M, Munoz F. Third-generation recombinant immunoblot assay to confirm hepatitis C virus-indeterminate serological samples. Vox Sang 1993; 64: 191192.
  • 7
    Damen M, Zaaijer HL, Cuypers HTM, Vrielink H, van der Poel CL, Reesink HW, Lelie PN. Reliability of the third-generation recombinant immunoblot assay for hepatitis C virus. Transfusion 1995; 35: 745749.
  • 8
    Gretch DR, Rosa C dela, Carithers RL Jr, Willson RA, Williams B, Corey L. Assessment of hepatitis C viremia using molecular amplification technologies: correlations and clinical implications. Ann Intern Med 1995; 123: 321329.
  • 9
    Gretch D, dela Rosa D, Corey L, Carithers R. Assessment of hepatitis C viremia using molecular amplification technologies. Viral Hepatitis Rev 1996; 2: 8596.
  • 10
    Magrin S, Craxi A, Fabiano C, Simonetti RG, Fiorentino G, Marino L, Diquattro O, et al. Hepatitis C viremia in chronic liver disease: relationship to interferon-α or corticosteroid treatment. Hepatology 1994; 19: 273279.
  • 11
    Yuki N, Hayashi N, Kasahara A, Hagiwara H, Takehara T, Oshita M, Katayama K, et al. Pretreatment viral load and response to prolonged interferon-α course for chronic hepatitis C. J Hepatol 1995; 22: 457463.
  • 12
    Yamada G, Takatani M, Kishi F, Takahashi M, Doi T, Tsuji T, Shin S, et al. Efficacy of interferon alfa therapy in chronic hepatitis C patients depends primarily on hepatitis C virus RNA level. Hepatology 1995; 22: 13511354.
  • 13
    Martinot-Peignoux M, Marcellin P, Pouteau M, Castelnau C, Boyer N, Poliquin M, Degott C, et al. Pretreatment serum hepatitis C virus RNA levels and hepatitis C virus genotype are the main and independent prognostic factors of sustained response to interferon alfa therapy in chronic hepatitis C. Hepatology 1995; 22: 10501056.
  • 14
    Magrin S, Craxi A, Fabiano C, Marino L, Fiorentino G, Lacono OL, Volpes R, et al. HCV viraemia is more important than genotype as a predictor of response to interferon in Sicily (Southern Italy). J Hepatol 1996; 25: 583590.
  • 15
    Damen M, Cuypers HTM, Zaaijer HL, Reesink HW, Schaasberg WP, Gerlich WH, Niesters HGM, et al. International collaborative study on the second EUROHEP HCV-RNA reference panel. J Virol Meth 1996; 58: 175185.
  • 16
    Scheuer PJ, Ashrafzadeh P, Sherlock S, Brown D, Dusheiko GM. The pathology of hepatitis C. Hepatology 1992; 15: 567571.
  • 17
    Lefkowitch JH, Schiff ER, Davis GL, Perrillo RP, Lindsay K, Boden-heimer HC Jr, Balart LA, et al. Pathological diagnosis of chronic hepatitis C: a multicenter comparative study with chronic hepatitis B. Gastro-enterology 1993; 104: 595603.
  • 18
    Bach N, Thung SN, Schaffner F. The histological features of chronic hepatitis C and autoimmune chronic hepatitis: a comparative analysis. Hepatology 1992; 15: 572577.
  • 19
    McDonnell WM, Lok ASF. Testing for hepatitis C virus RNA in serum: when and how? Viral Hepatitis Rev 1996; 2: 8183.
  • 20
    Gretch D, Corey L, Wilson J, dela Rosa C, Willson R, Carithers Jr R, Busch M, et al. Assessment of hepatitis C virus RNA levels by quantitative competitive RNA polymerase chain reaction: high-liter viremia correlates with advanced stage of disease. J Infect Dis 1994; 169: 12191225.
  • 21
    Benvegnu L, Pontisso P, Cavalletto D, Noventa F, Chemello L, Alberti A. Lack of correlation between hepatitis C virus genotypes and clinical course of hepatitis C virus-related cirrhosis. Hepatology 1997; 25: 211215.
  • 22
    Chemello L, Cavalletto D, Pontisso P, Bortolotti F, Donada C, Donadon V, Frezza M, et al. Patterns of antibodies to hepatitis C virus in patients with chronic non-A, non-B hepatitis and their relationship to viral replication and liver disease. Hepatology 1993; 17: 179182.
  • 23
    Bresters D, Zaaijer HL, Cuypers HTM, Reesink HW, Winkel IN, Van Exel-Oehlers PJ, Van Drimmelen AJ, et al. Recombinant immunoblot assay reaction patterns and hepatitis C virus RNA in blood donors and non-A, non-B hepatitis patients. Transfusion 1993; 33: 634638.
  • 24
    Qu D, Li J, Vitvitski L, Mechai S, Berby F, Tong S, Bailly F, et al. Hepatitis C virus genotypes in France: comparison of clinical features of patients infected with HCV type I and type II. J Hepatol 1994; 21: 7075.
  • 25
    Silini E, Bono F, Cividini A, Cerino A, Bruno S, Rossi S, Belloni G, et al. Differential distribution of hepatitis C virus genotypes in patients with and without liver function abnormalities. Hepatology 1995; 21: 285290.
  • 26
    Prati D, Capelli C, Zanella A, Mozzi F, Bosoni P, Pappalettera M, Zanuso F, et al. Influence of different hepatitis C virus genotypes on the course of asymptomatic hepatitis C virus infection. Gastroenterology 1996; 100: 178183.
  • 27
    Kleinman S, Alter H, Busch M, Holland P, Tegtmeier G, Nelles M, Lee S, et al. Increased detection of hepatitis C virus (HCV)-infected blood donors by a multiple-antigen HCV enzyme immunoassay. Transfusion 1992; 32: 805813.
  • 28
    Rossini A, Gazzola GB, Ravaggi A, Agostinelli E, Biasi L, Albertini A, Radaeli E, et al. Long-term follow-up of and infectivity in blood donors with hepatitis C antibodies and persistently normal alanine amino-transferase levels. Transfusion 1995; 35: 108111.
  • 29
    Zanella A, Conti D, Prati D, Mozzi F, Capelli C, Zanuso F, Fraquelli M, et al. Hepatitis C virus RNA and liver histology in blood donors reactive to a single antigen by second-generation recombinant immunoblot assay. Hepatology 1995; 21: 913917.
  • 30
    Prieto M, Olasa V, Verdu C, Cordoba J, Gisbert C, Rayon M, Carrasco D, et al. Does the healthy hepatitis C virus carrier state really exist? An analysis using polymerase chain reaction Hepatology 1995; 22: 413417.
  • 31
    Salmeron FJ, Palacios A, Perez-Ruiz M, Torres C, Oyonarte S, Fernan-dez-Montoya A, Ruiz-Extremera A. Epidemiology, serological markers, and hepatic disease of anti-HCV ELISA-2-positive blood donors. Dig Dis Sci 1996; 41: 19331938.
  • 32
    Shakil AO, Conry-Cantilena C, Alter JH, Hayashi P, Kleiner DE, Te-deschi V, Krawczynski K, et al. Volunteer blood donors with antibody to hepatitis C virus: clinical, biochemical, virologic, and histologic features. Ann Intern Med 1995; 123: 330337.
  • 33
    Busch M, Tobler L, Quan S, Wilber J, Johnson P, Polito A, Steane E, et al. A pattern of 5-1-1 and c100-3 only on hepatitis C virus (HCV) recombinant immunoblot assay does not reflect HCV infection in blood donors. Transfusion 1993; 33: 8488.
  • 34
    Martinot-Peignoux M, Marcellin P, Xu L, Bernuau J, Erlinger S, Benha-mou J, Larzul D. Reactivity of c33c antigen as a marker of hepatitis C virus multiplication. J Infect Dis 1992; 165: 595596.
  • 35
    Esteban JI, Lopez-Talavera JC, Genesca J, Madoz P, Viladomiu L, Mu-noz E, Martin-Vega C, et al. High rate of infectivity and liver disease in blood donors with antibodies to hepatitis C virus. Ann Intern Med 1991; 115: 443449.
  • 36
    Alberti A, Morsica G, Chemello L, Cavalletto D, Noventa F, Pontisso P, Ruol A. Hepatitis C viraemia and liver disease in symptom-free individuals with anti-HCV. Lancet 1992; 340: 697698.
  • 37
    Okanoue T, Yasui K, Sakamoto S, Minami M, Nagao Y, Itoh Y, Kagawa K, et al. Circulating HCV–RNA, HCV genotype, and liver histology in asymptomatic individuals reactive for anti-HCV antibody and their follow-up study. Liver 1996:; 16: 241247.
  • 38
    Garson JA, Tuke PW, Makris M, Briggs M, Machin SJ, Preston FE, Tedder RS. Demonstration of viraemia patterns in haemophiliacs treated with hepatitis-C-virus-contaminated factor VIII concentrates. Lancet 1990; 336: 10221025.
  • 39
    Farci P, Alter HJ, Wong D, Miller RH, Shih JW, Jett B, Purcell RH. A long-term study of hepatitis C virus replication in non-A, non-B hepatitis. N EnglJ Med 1991; 325: 98104.
  • 40
    Nguyen T, Sedghi-Vaziri A, Wilkes L, Mondala T, Pockros P, Lindsay K, McHutchison J. Fluctuations in viral load (HCV RNA) are relatively insignificant in untreated patients with chronic HCV infection. J Viral Hepatol 1996; 3: 7580.
  • 41
    Ghany MG, Chan TM, Sanchez-Pescador R, Urdea M, Lok ASF. Correlation between serum HCV RNA and aminotransferase levels in patients with chronic HCV infection. Dig Dis Sci 1996; 41: 22132218.
  • 42
    Serfaty L, Nousbaum JB, Elghouzzi MH, Giral P, Legendre C, Poupon R. Prevalence, severity, and risk factors of liver disease in blood donors positive in a second-generation anti-hepatitis C virus screening test. Hepatology 1995; 21: 725729.
  • 43
    Shindo M, Arai K, Sokawa Y, Okuno T. The virological and histological states of anti-hepatitis C virus-positive subjects with normal liver biochemical values. Hepatology 1995; 22: 418425.
  • 44
    Healey CJ, Chapman RWG, Fleming KA. Liver histology in hepatitis C infection: a comparison between patients with persistently normal or abnormal transaminases. Gut 1995; 37: 274278.
  • 45
    Lok ASF, Chien D, Choo QL, Chan TM, Chiu EKW, Cheng IKP, Houghton M, et al. Antibody response to core, envelope and nonstruc-tural hepatitis C virus antigens: comparison of immunocompetent and immunosuppressed patients. Hepatology 1993; 18: 497502.
  • 46
    Lau JYN, Davis GL, Brunson ME, Qian KP, Lin HJ, Quan S, DiNello R, et al. Hepatitis C virus infection in kidney transplant recipients. Hepatology 1993; 18: 10271031.
  • 47
    Donegan E, Wright TL, Roberts J, Ascher NL, Lake JR, Neuwald P, Wilber J, et al. Detection of hepatitis C after liver transplantation. Am J Clin Pathol 1995; 104: 673679.
  • 48
    Chan TM, Lok ASF, Cheng IKP, Chan RT. Prevalence of hepatitis C virus infection in hemodialysis patients: a longitudinal study comparing the results of RNA and antibody assays. Hepatology 1993; 17: 58.
  • 49
    Chan TM, Lok ASF, Cheng IKP, Chan RT. A prospective study of hepatitis C virus infection among renal transplant recipients. Gastroen-terology 1993; 104: 862868.
  • 50
    Courouce AM, LeMarrec N, Girault A, Ducamp S, Simon N. Anti-hepatitis C virus (anti-HCV) seroconversion in patients undergoing hemodialysis: comparison of second- and third-generation anti-HCV assays. Transfusion 1994; 34: 790795.
  • 51
    Soffredini R, Rumi MG, Lampertico P, Aroldi A, Tarantino A, Ponticelli C, Colombo M. Increased detection of antibody to hepatitis C virus in renal transplant patients by third-generation assays. Am J Kidney Dis 1996; 28: 437440.
  • 52
    Barrera JM, Bruguera M, Ercilla MG, Gil C, Celis R, Gil MP, Onorato M Del Valle, et al. Persistent hepatitis C viremia after acute self-limiting posttransfusion hepatitis C. Hepatology 1995; 21: 639644.
  • 53
    Lampertico P, Rumi M, Romeo R, Craxi A, Soffredini R, Biassoni D, Colombo M. A multicenter randomized controlled trial of recombinant interferon-α2b in patients with acute transfusion-associated hepatitis C. Hepatology 1994; 19: 1922.
  • 54
    Viladomiu L, Genesca J, Esteban JI, Allende H, Gonzalez A, Lopez-Talavera JC, Esteban R, et al. Interferon-α in acute posttransfusion hepatitis C: a randomized, controlled trial. Hepatology 1992; 15: 767769.
  • 55
    Hwang SJ, Lee SD, Chan CY, Lu RH, To KJ. A randomized controlled trial of recombinant interferonα -2b in the treatment of Chinese patients with acute post-transfusion hepatitis C. J Hepatol 1994; 21: 831836.
  • 56
    Takano S, Satomura Y, Omata M Japan Acute Hepatitis Cooperative Study Group. Effects of interferon beta on non-A, non-B acute hepatitis: a prospective, randomized, controlled-dose study. Gastroenterology 1994; 107: 805811.
  • 57
    Omata M, Yokosuka O, Takano S, Kato N, Hosoda K, Imazeki F, Tada M, et al. Resolution of acute hepatitis C after therapy with natural beta interferon. Lancet 1991; 338: 914915.
  • 58
    Yano M, Kumada M, Kage M, Ikeda K, Shimametsu K, Inoue O, Hashimoto E, et al. The long-term pathological evolution of chronic hepatitis C. Hepatology 1996; 23: 13341340.
  • 59
    Rumi M, Del Ninno E, Parravicini ML, Romeo R, Soffredini R, Donato MF, Wilber J, et al. A prospective, randomized trial comparing lympho-blastoid to recombinant interferon alfa 2a as therapy for chronic hepatitis C. Hepatology 1996; 24: 13661370.
  • 60
    Chemello L, Bonetti P, Cavalletto L, Talato F, Donadon V, Casarin P, Belussi F, et al. Randomized trial comparing three different regimens of alpha-2a-interferon in chronic hepatitis C. Hepatology 1995; 22: 700706.
  • 61
    Tsubota A, Kumada H, Chayama K, Arase Y, Saitoh S, Koida I, Mura-shima N, et al. Relationship between pretreatment viremia level and response to interferon -α therapy in chronic hepatitis C differs in viral type 1 and 2 infections. Dig Dis Sci 1996; 41: 19251932.
  • 62
    Pagliaro L, Craxi A, Gamma C, Tin F, DiMarco V, Lacono OL, Almasio P. Interferon -α for chronic hepatitis C: an analysis of pretreatment clinical predictors of response. Hepatology 1994; 19: 820828.
  • 63
    Tsubota A, Chayama K, Ikeda K, Yasuji A, Koida I, Saitoh S, Hashimoto M, et al. Factors predictive of response to interferon-α therapy in hepatitis C virus infection. Hepatology 1994; 19: 10881094.
  • 64
    Haber MM, West A, Haber AD, Reuben A. Relationship of aminotrans-ferases to liver histological status in chronic hepatitis C. Am J Gas-troenterol 1995; 90: 12501257.
  • 65
    Gordon SC, Kodali VP, Silverman AL, Dmuchowski CF, Urdea MS, Chan CS, Wilber JC. Levels of hepatitis C virus RNA and liver histology in chronic type C hepatitis. Am J Gastroenterol 1994; 89: 14581461.
  • 66
    Smith DB, Davidson F, Yap PL, Brown H, Kolberg JH, Detmer J, Urdea M, et al. Levels of hepatitis C virus in blood donors infected with different viral genotypes. J Infect Dis 1996; 173: 727730.
  • 67
    Zeuzem S, Franke A, Lee JH, Herrmann G, Ruster B, Roth WK. Phylo-genetic analysis of hepatitis C virus isolates and their correlation to viremia, liver function tests, and histology. Hepatology 1996; 24: 10031009.
  • 68
    McCormick SE, Goodman ZD, Maydonovitch CL, Sjogren MH. Evaluation of liver histology, ALT elevation, and HCV RNA liter in patients with chronic hepatitis C. Am J Gastroenterol 1996; 91: 15161522.
  • 69
    Hagiwara H, Hayashi N, Mita E, Naito M, Kasahara A, Fusamoto H, Kamada T. Quantitation of hepatitis C virus RNA in serum of asymptomatic blood donors and patients with type C chronic liver disease. Hepatology 1993; 17: 545550.
  • 70
    Naito M, Hayashi N, Hagiwara H, Hiramatsu N, Kasahara A, Fusamoto H, Kamada T. Serum hepatitis C virus RNA quantity and histological features of hepatitis C virus carriers with persistently normal ALT levels. Hepatology 1994; 19: 871875.
  • 71
    Naito M, Hayashi N, Moribe T, Hagiwara H, Mita E, Kanazawa Y, Kasahara Y, et al. Hepatitis C viral quasispecies in hepatitis C virus carriers with normal liver enzymes and patients with type C chronic liver disease. Hepatology 1995; 22: 407412.
  • 72
    Nousbaum JB, Pol S, Nalpas B, Landais P, Berthelot P, Brechot C, and the Collaborative Study Group. Hepatitis C virus type Ib (II) infection in France and Italy. Ann Intern Med 1995; 122: 161168.
  • 73
    Kato N, Yokosuka O, Hosoda K, Ito Y, Ohio M, Omata M. Quantification of hepatitis C virus by competitive reverse transcription-polymer-ase chain reaction: increase of the virus in advanced liver disease. Hepatology 1993; 18: 1620.
  • 74
    Dusheiko G, Schmilovitz-Weiss H, Brown D, McOmish F, Yap PL, Sherlock S, McLntyre N, et al. Hepatitis C virus genotypes: an investigation of type-specific differences in geographic origin and disease. Hepatology 1994; 19: 1318.
  • 75
    Pozzato G, Kaneko S, Moretti M, Croce LS, Franzin F, Unoura M, Bercich L, et al. Different genotypes of hepatitis C virus are associated with different severity of chronic liver disease. J Med Virol 1994; 43: 291296.
  • 76
    Chen CH, Sheu JC, Wang JT, Huang GT, Yang PM, Lee HS, Lee CZ, et al. Genotypes of hepatitis C virus in chronic liver disease in Taiwan. J Med Virol 1994; 44: 234236.
  • 77
    Silini E, Bottelli R, Asti M, Bruno S, Candusso ME, Brambilla S, Bono F, et al. Hepatitis C virus genotypes and risk of hepatocellular carcinoma in cirrhosis: a case-control study. Gastroenterology 1996; 111: 199205.
  • 78
    Zein NN, Rakela J, Krawitt EL, Reddy KR, Tominaga T, Persing DH, et al. Hepatitis C virus genotypes in the United States: epidemiology, pathogenicity, and response to interferon therapy. Ann Intern Med 1996; 125: 634639.
  • 79
    Ichimura H, Tamura I, Kurimura O, Koda T, Mizui M, Tsuchie H, Kurimura T. Hepatitis C virus genotypes, reactivity to recombinant immunoblot assay 2 antigens and liver disease. J Med Virol 1994; 43: 212215.
  • 80
    Pol S, Thiers V, Nousbaum JB, Legendre C, Berthelot P, Kreis H, Brechot C. The changing relative prevalence of hepatitis C virus genotypes: evidence in hemodialyzed patients and kidney recipients. Gastroenterology 1995; 108: 581583.
  • 81
    Takada N, Takase S, Enomoto N, Takada A, Date T. Clinical backgrounds of the patients having different types of hepatitis C virus genomes. J Hepatol 1992; 14: 3540.
  • 82
    Mita E, Hayashi N, Kanazawa Y, Hagiwara H, Ueda K, Kasahara A, Fusamoto H, et al. Hepatitis C virus genotype and RNA liter in the progression of type C chronic liver disease. J Hepatol 1994; 21: 468473.
  • 83
    Lau JYN, Davis GL, Prescott LE, Maertens G, Lindsay KL, Qian K, Mizokami M, et al. Distribution of hepatitis C virus genotypes deter-mined by line probe assay in patients with chronic hepatitis C seen at tertiary referral centers in the United States. Ann Intern Med 1996; 124: 868876.
  • 84
    Kobayashi M, Tanaka E, Sodeyama T, Urushihara A, Matsumoto A, Kiyosawa K. The natural course of chronic hepatitis C: a comparison between patients with genotypes 1 and 2 hepatitis C viruses. Hepatology 1996; 23: 695699.
  • 85
    Gane EJ, Portmann BC, Naoumov NV, Smith HM, Underbill JA, Donaldson PT, Maertens G, et al. Long-term oulcome of hepatitis C infection after liver transplantation. N Engl J Med 1996; 334: 815820.
  • 86
    Feray C, Gigou M, Samuel D, Paradis V, Mishiro S, Maertens G, Reynes M, et al. Influence of the genotypes of hepatitis C virus on the severity of recurrent liver disease after liver transplantation. Gastroenterology 1995; 108: 10881096.
  • 87
    Zhou S, Terrault NA, Ferrell L, Hahn JA, Lau JYN, Simmonds P, Roberts JP, et al. Severity of liver disease in liver transplantation recipi-ents with hepatitis C virus infection: relationship to genotype and level of viremia. Hepatology 1996; 24: 10411046.
  • 88
    Kobayashi Y, Watanabe S, Konishi M, Yokoi M, Kakehashi R, Kaito M, Kondo M, et al. Quantitation and typing of serum hepatitis C virus RNA in patients with chronic hepatitis C treated with interferon-β. Hepatology 1993; 18: 13191325.
  • 89
    Hagiwara H, Hayashi N, Mita E, Takehara T, Kasahara A, Fusamoto H, Kamada T. Quantitative analysis of hepatitis C virus RNA in serum during interferon alfa therapy. Gastroenterology 1993; 104: 877883.
  • 90
    Hino K, Sainokami S, Shimoda K, Iino S, Wang Y, Okamoto H, Miya-kawa Y, et al. Genotypes and titers of hepatitis C virus for predicting response to interferon in patients with chronic hepatitis C. J Med Virol 1994; 42: 299305.
  • 91
    Mito E, Hayashi N, Hagiwara H, Ueda K, Kanazawa Y, Kasahara A, Fusamoto H, et al. Predicting interferon therapy efficacy from hepatitis C virus genotype and RNA titer. Dig Dis Sci 1994; 39: 977982.
  • 92
    Hayashi J, Ohmiya M, Kishihara Y, Tani Y, Kinukawa N, Ikematsu H, Kashiwagi S. A statistical analysis of predictive factors of response to human lymphoblastoid interferon in patients with chronic hepatitis C. Am J Gastroenterol 1994; 89: 21512156.
  • 93
    Aiyama T, Yoshioka K, Takayanagi M, Iwata K, Okumura A, Kakumu S. Serum HCV RNA titer al the end of interferon therapy predicts the long term outcome of treatment. J Hepatol 1995; 23: 497502.
  • 94
    Toyoda H, Kumada T, Nakano S, Takeda I, Sugiyama K, Osada T, Kiriyama S, et al. Quasispecies nalure of hepatitis C virus and response to alpha interferon : significance as a predictor of direct response to interferon. J Hepatol 1997; 26: 613.
  • 95
    Aiyama T, Yoshioka K, Hirofuji H, Kusakabe A, Yamada M, Tanaka K, Kakumu S. Changes in serum hepatitis C virus RNA titer and response to interferon therapy in patients with chronic hepatitis C. Dig Dis Sci 1994; 10: 22442249.
  • 96
    Kasahara A, Hayashi N, Hiramatsu N, Oshita M, Hagiwara H, Katayama K, Kato M, et al. Ability of prolonged interferon treatment to suppress relapse after cessation of therapy in patients with chronic hepatitis C: a multicenter randomized controlled trial. Hepatology 1995; 21: 291297.
  • 97
    Hawkins A, Davidson F, Simmonds P. Comparison of plasma virus loads among individuals infected with hepatitis C virus (HCV) genotypes 1,2, and 3 by Quantiplex HCV RNA assay versions 1 and 2, Roche monitor assay, and an in-house limiting dilution method. J Clin Microbiol 1997; 35: 187192.
  • 98
    Yoshioka K, Kakumu S, Wakita T, Ishikawa T, Itoh Y, Takayanagi M, Higashi Y, et al. Detection of hepatitis C virus by polymerase chain reaction and response to interferon -α therapy: relationship to genotypes of hepatitis C virus. Hepatology 1992; 16: 293299.
  • 99
    Orito E, Mizokami M, Mizoguchi N, Ohba KI, Tohnai M, Yamanaka H, Oguri T, et al. Hepatitis C virus serotype II responds more favorably to interferon -α therapy. J Hepatol 1994; 21: 130132.
  • 100
    Lau JYN, Mizokami M, Ohno T, Diamond DA, Kniffen J, Davis GL. Discrepancy between biochemical and virological responses in interferon-α in chronic hepatitis C. Lancet 1993; 342: 12081209.
  • 101
    Chemello L, Cavalletto L, Casarin C, Bonetti P, Bernardinello E, Pon-tisso P, Donada C, et al. Persistent hepatitis C viremia predicts late relapse after sustained response to interferon-α in chronic hepatitis C. Ann Intern Med 1996; 124: 10581060.
  • 102
    Davis GL, Lindsay K, Albrecht J, Bodenheimer HC Jr, Balart LA, Per-rillo RP, Dienstag JL, et al. Clinical predictors of response to recombi-nant interferon-α treatment in patients with chronic non–A, non-B hepatitis (hepatitis C). J Viral Hepatitis 1994; 1: 5563.
  • 103
    Marcellin P, Pouteau M, Martinot–Peignoux M, Degos F, Duchatelle V, Boyer N, Lemonnier C, et al. Lack of benefit of escalating dosage of interferon alfa in patients with chronic hepatitis C. Gastroenterology 1995; 109: 156165.
  • 104
    Lindsay KL, Davis Gl, Schiff ER, Bodenheimer HC, Balart LA, Dienstag JL, Perrillo RP, et al. Response to higher doses of interferon alfa-2b in patients with chronic hepatitis C: a randomized multicenter trial. Hepatology 1996; 24: 10341040.
  • 105
    Poynard T, Bedossa P, Chevallier M, Mathurin P, Lemonnier C, Trepo C, Couzigou P, et al. A comparison of three interferon alfa-2b regimens for the long-term treatment of chronic non-A, non-B hepatitis. N Engl J Med 1995; 332: 14571462.
  • 106
    Ampurdanes S, Olmedo E, Maluenda MD, Forns X, Lopez-Labrador FX, Costa J, Sanchez-Tapias JM, et al. Permanent response to alpha-interferon therapy in chronic hepatitis C is preceded by rapid clearance of HCV-RNA from serum. J Hepatol 1996; 25: 827832.
  • 107
    Orito E, Mizokami M, Suzuki K, Ohba K, Ohno T, Mori M, Hayashi K, et al. Loss of serum HCV RNA at week 4 of interferon-a therapy is associated with more favorable long-term response in patients with chronic hepatitis C. J Med Virol 1995; 46: 109115.